Non-invasive prenatal testing (NIPT) is a screening test offered during pregnancy and is commonly used to determine the risk of a fetus being born with certain genetic abnormalities, such as Down syndrome, Edwards syndrome, Patau syndrome, and disorders affecting the sex chromosomes (X and Y). The test analyzes small DNA fragments circulating in the blood of pregnant women and is also known as a cell-free DNA (cfDNA) screen. There must be enough fetal cfDNA in the mother's blood to identify fetal chromosomal abnormalities. It is important to note that this screening test only estimates the likelihood that the fetus has a specific disorder and does not diagnose the condition. There are several NIPT methods available to analyze fetal cfDNA, the most common method is to count all cfDNA fragments (fetal and maternal) to predict risk.
CD Genomics offers a wide range of NIPT reference products to help you screen for the most common fetal aneuploidies, other autosomal and sex chromosome aneuploidies, as well as some microdeletions, large copy number variants and monogenic disorders.
NIPT is one of the fastest growing pregnancy screening tests due to its superior sensitivity and is widely adopted by clinical laboratories worldwide. We develop reliable NIPT reference products for monitoring the process quality control of sample extraction, library preparation and up-sequencing of NIPT kits.
Our NIPT reference products use human-derived cell line-derived gDNA as raw material, which can highly mimic real clinical samples by fragmentation and incorporation into human-derived plasma. They are widely used by various laboratories for cfDNA testing of pregnant women by genome-wide methods.
Our NIPT reference products are derived from human-derived cell lines.
Types of chromosomal abnormalities for which customizable NIPT reference products are available:
Explore Our Non-Invasive Prenatal Testing (NIPT) Reference Products:
Cat. No. | Product Name | Brief Description | Inquiry | Basket |
---|---|---|---|---|
NIPTR001 | CD T21 10% cfDNA Plasma Reference | CD T21 10% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR002 | CD T21 5% cfDNA Plasma Reference | CD T21 5% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR003 | CD T21 3.5% cfDNA Plasma Reference | CD T21 3.5% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR004 | CD T13 10% cfDNA Plasma Reference | CD T13 10% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR005 | CD T13 5% cfDNA Plasma Reference | CD T13 5% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR006 | CD T13 3.5% cfDNA Plasma Reference | CD T13 3.5% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR007 | CD T18 10% cfDNA Plasma Reference | CD T18 10% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR008 | CD T18 5% cfDNA Plasma Reference | CD T18 5% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR009 | CD T18 3.5% cfDNA Plasma Reference | CD T18 3.5% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. | ||
NIPTR010 | CD 1p36 Missing 10% cfDNA Plasma Reference | CD 1p36 Missing 10% cfDNA Plasma Reference is suitable for the detection of free DNA (cfDNA) in the peripheral blood of pregnant women by the massive-parallel sequencing MPS. |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×